(03.06.2026) Switzerland's biotechnology industry reported a strong year in 2025. According to the Swiss Biotech Report 2026, the sector generated revenues of CHF 7.5 billion, up from CHF 7.2 billion in 2024, while continuing to attract international investment.
Biotech fundraising increased by 2.1% in 2025 to CHF 2.6 billion. This growth was driven by privately held companies, whose funding increased by 38% to CHF 1.15 billion. These companies accounted for 45% of total investment in the sector. Windward Bio (CHF 186 million), GlycoEra (CHF 104 million), Orbis Medicine (CHF 84 million), Nucidium (CHF 79 million) and Rhygaze (CHF 78 million) completed the largest funding rounds.
Among publicly listed companies, BioVersys completed Europe's largest initial public offering in February 2025, raising USD 88 million. MoonLake (CHF 490 million), Oculis (CHF 274 million), Idorsia (CHF 216 million) and ADC Therapeutics (CHF 129 million) also raised substantial additional funding.
The year 2025 was also characterized by sustained merger and acquisition activity and partnership agreements. Zurich-based CDR-Life signed a global licensing agreement with German pharmaceutical company Boehringer Ingelheim (worth up to USD 456 million). In addition, Basel-based Windward Bio entered into an agreement with the Chinese company Qyuns Therapeutics (worth up to USD 700 million).
Research and development (R&D) investment, however, declined slightly to CHF 2.5 billion (-3.8% compared with 2024). Employment nevertheless reached a record level. Across Switzerland, the industry now accounts for more than 21,000 full-time equivalent jobs. While approvals of new biotech products slowed in Europe, the United States and Switzerland in 2025, they increased in key markets such as China and Canada.
Last modification 03.06.2026
